Trials / Terminated
TerminatedNCT00031473
Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients
A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (planned)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) · NIH
- Sex
- All
- Age
- 5 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and effectiveness of ribavirin, administered as an aerosol, in preventing progression of upper respiratory tract RSV infection to RSV pneumonia in bone marrow and peripheral blood transplant recipients.
Detailed description
The study enrolls 90 transplant recipients with positive nasal/throat culture specimens for Respiratory Syncytial Virus (RSV) infection. Patients are randomized into one of two groups: investigational treatment or standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Virazole (Ribavirin) Inhalation Solution |
Timeline
- Start date
- 1997-11-01
- Completion
- 2003-03-01
- First posted
- 2002-03-07
- Last updated
- 2010-08-27
Locations
11 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00031473. Inclusion in this directory is not an endorsement.